activity, which leads to the phosphorylation of tyrosine residues in the intracellular domain of the receptors (van 1 Corresponding author der Geer et al., 1994) . These serve as docking sites for a number of SH2-and PTB-domain containing proteins We have analyzed ErbB receptor interplay induced by (Kavanaugh and Williams, 1994; Cohen,G.B. et al., 1995 Riese et al. 1996) ; neu ErbB-2, suggesting that ErbB-2 has a role in the lateral differentiation factors (NDFs)/heregulins (Peles and transmission of signals between other ErbB receptors. Yarden, 1993) , which are ligands of ErbB-3 and ErbB-4 Finally, ErbB-1 activated by all EGF-related peptides (Plowman et al., 1993b; , the (EGF, HB-EGF, BTC and NDF) couples to SHC, respective low and high affinity receptors (Tzahar et al., whereas only ErbB-1 activated by its own ligands 1994). associates with and phosphorylates Cbl. These results By binding to the ECD of their respective receptors, provide the first biochemical evidence that a given ErbB EGF-related peptides induce not only receptor homodimers receptor has distinct signaling properties depending on but also heterodimers. Consequently, although none of its dimerization.
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. Moreover, EGF and NDF receptors have been The ErbB family of receptor tyrosine kinases (RTKs) or shown to compete for dimerization with ErbB-2 subclass I RTKs comprises four members: epidermal (Karunagaran et al., 1995; Chen et al., 1996) . By means growth factor receptor (EGFR)/ErbB-1 (Ullrich et al., of intracellular expression of an endoplasmic reticulum 1984), ErbB-2 (Yamamoto et al., 1986) , ErbB-3 (Kraus (ER)-targeted single chain antibody (scFv) that leads to et Plowman et al., 1990) and ErbB-4 (Plowman the specific and stable loss of cell surface ErbB-2 (Beerli et al., 1993a) . The four proteins are widely expressed in et al., 1994) , we have previously shown that: (i) ErbB-2 epithelial, mesenchymal and neuronal tissues and play enhances EGF-induced tyrosine phosphorylation of fundamental roles during development (Gassmann et al., ErbB-1 and NDF-induced tyrosine phosphorylation of 1995; Lee et al., 1995; Sibilia and Wagner, 1995;  ErbB-3 and ErbB-4 (Beerli et al. 1995; Graus-Porta et al., Threadgill et al., 1995) . Interest in the ErbB family of 1995); (ii) ErbB-2 potentiates and prolongs the signal RTKs is high due also to the involvement of some of its transduction pathways elicited by EGF and NDF (Beerli members in human cancers (Hynes and Stern, 1994; Karunagaran et al., Salomon et al., 1995 . In addition, we and others have shown that ErbB-2 Subclass I RTKs have an extracellular domain (ECD) which bears two cysteine-rich clusters and is responsible increases the affinity of both EGF and NDF for their receptors (Wada et al., 1990; Sliwkosky et al., 1994; Karunagaran et al., 1996) . Together, these results suggest that ErbB-2 acts as a common receptor subunit of all the other ErbB proteins and that the physiological receptors for the EGF-related peptides are ErbB-2-containing heterodimers. However, several recent observations apparently argue against this model. First, it has been suggested that ErbB-1-ErbB-3 heterodimers occur in cell lines overexpressing ErbB-1, where EGF can efficiently elevate tyrosine phosphorylation of ErbB-3 (Kim et al., 1994; Soltoff et al., 1994) . Second, in cells that express moderate levels of the four proteins, EGF, HB-EGF and BTC not only activate their respective receptors and ErbB-2, but also ErbB-3 (Beerli and Hynes, 1996) . Third, cooperative signaling of ErbB-3 and ErbB-4 with not only ErbB-2 but also ErbB-1 has been demonstrated when the receptors were expressed in cells devoid of ErbB proteins (Cohen,B.D. et al., 1996; Pinkas-Kramarski et al., 1996; Zhang et al., 1996) . Finally, expression of different combinations of ErbB receptors in Ba/F3 hematopoietic cells has revealed that all heterodimers can be formed in response to the appropriate ligand (Riese et al., 1995 (Riese et al., , 1996 .
Expression of recombinant ErbB receptors in pairwise combinations is a viable approach to study their function. However, the four ErbB proteins are often co-expressed and this approach does not allow delineation of which ErbB receptor interactions are biologically relevant. Different heterodimers have been shown to elicit very different biological responses (Riese et al., 1995 (Riese et al., , 1996 , implying we have down-regulated the cell surface expression of ErbB-1 and ErbB-2 in a number of cell lines that coexpress various amounts of the four ErbB proteins. To do ErbB-1 but not ErbB-2 resulted in increased expression levels (Figures 1A and 4A) , possibly due to an altered so, ErbB-2-specific scFv-5R (Beerli et al., 1994) has been expressed in T47D and A431 turnover of the ER-retained protein. We previously made a similar observation with the ER retention of a pointcells, leading to a complete loss of cell surface ErbB-2 and to its functional inactivation. ErbB-1-specific scFvmutated, constitutively active ErbB-2 (Beerli et al., 1994) . We analyzed ErbB-2 activation by EGF-related peptides R1R has been expressed in T47D cells (Jannot et al., 1996) , leading to a dramatic reduction in cell surface in T47D/R1R and T47D/5R sublines, as well as in T47D/ puro vector control cells ( Figure 1A ). EGF, HB-EGF, ErbB-1. This approach has enabled us to analyze in more detail EGF-, HB-EGF-, BTC-and NDF-induced signaling BTC and NDF activated ErbB-2 in the control cells but not in T47D/5R cells, due to its disappearance from and to unravel a hierarchy guiding the ligand-induced coordinated action of ErbB receptors. the plasma membrane. In T47D/R1R cells, displaying dramatically reduced levels of cell surface ErbB-1 (Jannot et al., 1996) , the EGF agonists did not significantly
Results
stimulate ErbB-2, whereas NDF led to phosphotyrosine levels comparable with those in the control cells. This is scFv-mediated intracellular retention of ErbB-1 results in impaired ErbB-2 activation by EGF in accordance with the fact that NDF neither binds nor activates ErbB-1 in cells that co-express the four ErbB agonists but not by NDF To investigate in more detail ligand-induced ErbB receptor proteins ( Figure 4A ; Beerli and Hynes, 1996) . interactions, cell surface expression of either ErbB-1 or ErbB-2 was selectively down-regulated in T47D cells by ErbB-2 enhances ErbB-4 tyrosine phosphorylation induced by EGF-related peptides intracellular expression of scFv-R1R (Jannot et al., 1996) or scFv-5R (Beerli et al., 1994 (Beerli et al., , 1995 Various EGF-related peptides stimulate ErbB-4 tyrosine phosphorylation in T47D cells, the most efficient ones being 1995) respectively. Interestingly, intracellular retention of the ErbB-4 ligands BTC and NDF (Beerli and Hynes, 1996) . To study the mechanism of its activation, we examined the involvement of ErbB-1 and ErbB-2 in stimulation of ErbB-4 phosphorylation ( Figure 1B ). Intracellular retention of ErbB-2 resulted in impaired activation of ErbB-4 by BTC and NDF, suggesting that activation of this receptor by its ligands involves ErbB-2-containing heterodimers. Moreover, EGF-and HB-EGF-induced tyrosine phosphorylation of ErbB-4 was also impaired in T47D/5R cells, demonstrating that even activation of ErbB-4 by ErbB-1 ligands involves ErbB-2. In accordance with the fact that BTC and NDF directly interact with ErbB-4, down-regulation of cell surface ErbB-1 did not affect ErbB-4 activation by these ligands, while it abolished activation of ErbB-4 by EGF. Surprisingly, HB-EGF was able to regulate ErbB-4 tyrosine phosphorylation in an ErbB-1-independent manner, suggesting that an additional receptor for this ligand must exist.
ErbB-2 enhances ErbB-3 tyrosine phosphorylation and association with p85 NDFs, the ErbB-3 ligands, activate ErbB-3 in diverse cell lines, and ErbB-2 dramatically enhances this effect (Beerli et al., 1995; . Treatment of cells with EGF and BTC also results in increased ErbB-3-tyrosine phosphorylation (Beerli and Hynes, 1996) . Since both peptides bind and activate ErbB-1 and stimulate ErbB-2 tyrosine phosphorylation, we examined whether scFv-mediated ER retention of either of the two receptors would interfere with ErbB-3 activation ( Figure 2A ). When compared with control cells, the EGF-and BTC-induced tyrosine phos- several consensus motifs in the receptor intracellular domain (Fedi et al., 1994; Prigent and Gullick, 1994) . Moreover, ER retention of ErbB-2 dramatically impairs 3A). Intracellular expression of ErbB-2-specific scFv in A431 cells ( Figure 3A , left panel) resulted in the disappear-NDF-induced recruitment of p85 (Beerli et al., 1995) . Therefore, we examined whether EGF-, HB-EGF-and ance of ErbB-2 from the plasma membrane (our unpublished data) and in an increased electrophoretic mobility BTC-induced ErbB-3 coupling to p85 was affected in cells lacking ErbB-2 ( Figure 2B ). Complex formation of ( Figure 3A , right panel). The A431 derivatives were treated with different ErbB ligands and ErbB-3 tyrosine p85 with ErbB-3 was diminished in response to all the peptides tested in T47D/5R cells. This result parallels the phosphorylation was examined ( Figure 3B ). Activation of ErbB-3 observed in the control cells was reduced in A431/ reduced tyrosine phosphorylation levels of ErbB-3 in these cells and corroborates the role of ErbB-2 in mediating 5R cells, demonstrating that ErbB-2 mediates, at least in part, ErbB-3 activation by these ligands even in cells ErbB-3 activation not only by NDF, but also by the other ErbB receptors ligands, EGF, HB-EGF and BTC.
expressing high levels of ErbB-1. To confirm that activation of ErbB-3 by EGF occurs It has been suggested that EGF-induced tyrosine phosphorylation of ErbB-3 occurs by direct ErbB-1/ via a direct interaction between ErbB-2 and ErbB-3, we used the ErbB-2 overexpressing human mammary ErbB-3 crosstalk in A431 human carcinoma cells (Soltoff et al., 1994) . A431 cells have 1ϫ10 6 EGFR molecules, carcinoma cell line SKBR3. Cells treated with EGF showed increased levels of ErbB-2 co-immunoprecipitatwhereas T47D cells have only 7000 molecules (Jannot et al., 1996) . It would be reasonable to assume that due ing with ErbB-3, indicating a direct interaction between ErbB-2 and ErbB-3 in response to EGF ( Figure 3C ). to the high receptor density in A431 cells, EGF would trigger ErbB-1-ErbB-3 heterodimers and thereby activate ErbB-3 in an ErbB-2 independent manner. To examine ErbB-2 differentially modulates ErbB-1 activation by EGF-related peptides this directly, A431 cells were infected with a retrovirus encoding scFv-5R, as well as with a vector control virus, All EGF agonists induce ErbB-1 tyrosine phosphorylation in T47D mammary epithelial cells (Beerli and Hynes, 1996) giving rise to the sublines A431/5R and A431/puro ( Figure Fig. 4 . Ligand-induced ErbB-1 tyrosine phosphorylation and complex formation with SHC. The indicated cell lines were serum starved for 24 h and, prior to lysis, treated with 4 nM diverse peptides for 10 min or left untreated. ErbB-1 was immunoprecipitated from 1 mg total protein and immunocomplexes were subjected to SDS-PAGE (7% gel) and analyzed by Western blotting with (A, upper panel) a phosphotyrosine-specific mAb or (B) an SHC-specific antibody. Bars results shown are typical and representative of three independent with an scFv-specific antiserum. (Right) Aliquots of 100 μg total experiments. protein were subjected to SDS-PAGE (7.5% gel), blotted and analyzed for ErbB-2 expression with 21N antiserum. C, control cells. (B) Ligand-induced ErbB-3 tyrosine phosphorylation. A431 derivative cell lines were serum starved for 24 h and, prior to lysis, treated with 4 nM of one of the indicated peptide ligands for 10 min or left co-expressing the four ErbB receptors, including T47D, untreated. ErbB-3 was immunoprecipitated from 1 mg total protein MCF7, MCF10A, OVCAR3 and A431 cells (Beerli and and immunocomplexes were subjected to SDS-PAGE (7% gel) and Hynes, 1996; our unpublished data). Thus, we investigated analyzed by Western blotting with a phosphotyrosine-specific mAb.
whether ErbB-2 interferes with this event by examining
The results shown are typical and representative of two independent experiments. (C) EGF-induced ErbB-2-ErbB-3 interaction. SKBR3
ErbB-1 activation in the presence and absence of ErbB-2 cells were serum starved for 24 h and, prior to lysis, treated with ( Figure 4A ). Indeed, NDF was able to activate ErbB-1 10 nM EGF for 10 min or left untreated. ErbB-3 was in the absence of ErbB-2, revealing that ErbB receptor immunoprecipitated from 1 mg total protein and immunocomplexes interactions are hierarchical in nature. Thus, ErbB-2 is the were subjected to SDS-PAGE (7% gel) and analyzed by Western blotting with ErbB-2-specific antiserum (left). The filter was stripped preferred heterodimerization partner of NDF receptors and and reprobed with ErbB-3-specific antibody (right).
thereby prevents activation of ErbB-1 in a natural cellular context.
The SH2/PTB domain-containing adaptor protein SHC has been shown to couple RTKs to the Ras/MAPK pathway and ErbB-2 enhances the EGF effect (Graus-Porta et al., by interacting with specific phosphorylated tyrosines on 1995). Thus, we examined whether activation of ErbB-1 the receptors (Pelicci et al., 1992 ; Rozakis-Adcock et al., by two other EGF agonists, HB-EGF and BTC, was also 1992). We therefore examined whether ErbB-2 affects the dependent upon the presence of ErbB-2 in the plasma memligand-induced ErbB-1 interaction with SHC ( Figure 4B ). brane ( Figure 4A ). In T47D/5R cells, stimulation with both All ErbB-1 ligands induced complex formation of ErbB-1 ligands led to lower levels of ErbB-1 tyrosine phosphorylwith SHC in control cells, which was reduced in T47D/5R ation than in the control cells, indicating that ErbB-1-cells, consistent with diminished tyrosine phosphorylation ErbB-2 heterodimers are also involved in ErbB-1 activation of the receptor. The opposite observation was made with in response to HB-EGF and BTC.
NDF, since it could promote ErbB-1-SHC association Various reports have shown NDF-induced ErbB-1 activonly in the absence of ErbB-2. This is in accordance with ation when it was co-expressed with either ErbB-3 or ErbB-4 NDF-induced tyrosine phosphorylation of ErbB-1 and (Riese et al., 1995; Cohen,B.D. et al., 1996; Zhang et al., demonstrates that NDF-activated ErbB-1 is a functional 1996). However, we were unable to detect ErbB-1 tyrosine phosphorylation in response to NDF in cell lines naturally receptor able to couple to downstream signaling molecules. . Time course of BTC-induced ERK1 activation. The T47D sublines T47D/puro and T47D/5R were starved in serum-free medium for 24 h and, prior to lysis, treated with 1 nM BTC for the indicated times. The MAPK isoform ERK1 was immunoprecipitated from 200 μg cell lysate and in vitro kinase assays were performed using MBP as substrate. Proteins were subjected to SDS-PAGE (15% gel), blotted and phosphorylation of MBP was quantitated with a PhosphorImager.
sufficient to promote phosphorylation of Cbl as well as its association with ErbB-1. These results suggest that NDF-activated ErbB-1 has signaling properties distinguishable from those of ErbB-1 activated by EGF agonists. the ErbB-3 and ErbB-4 ligand NDF (Beerli et al., 1995;  mg total protein and the immunocomplexes were subjected to SDS- . BTC is the prototype member in BTC-triggered MAPK activation ( Figure 6 ). BTC rapidly activated the MAPK isoform ERK1 in both T47D sublines. However, in scFv-5R-expressing cells the fold scFv-mediated intracellular retention of ErbB-2 results in impaired ligand-induced coupling to Cbl induction was reduced and activity returned to basal levels much more rapidly then in the control cells. Therefore, Stimulation of ErbB-1 (Galisteo et al., 1995) , but not of other ErbB receptors (Levkovitz et al., 1996) , has been we conclude that the presence of ErbB-2 enhances and prolongs MAPK activity in response to the three different shown to result in tyrosine phosphorylation and association with the downstream substrate Cbl. This prompted us classes of EGF-related peptides, those binding ErbB-1, those binding ErbB3 and ErbB-4, and those binding to analyze Cbl tyrosine phosphorylation and complex formation with ErbB-1 in response to diverse ligands in ErbB-1 and ErbB-4. the presence and absence of ErbB-2 ( Figure 5 ). In T47D/ puro control cells, the EGF agonists, but not NDF, sigDiscussion nificantly induced Cbl tyrosine phosphorylation, in agreement with their ability to stimulate ErbB-1. This was
scFv-mediated intracellular retention of ErbB-2 impairs BTC-dependent activation of MAPK
In this study we have analyzed EGF-, HB-EGF-, BTCand NDF-induced signaling in several human epithelial reduced in T47D/5R cells in accordance with the reduced activation of ErbB-1 ( Figure 5A ). Ligand-induced tyrosine cell lines co-expressing all four presently known ErbB receptors. Single chain antibody-mediated down-regulaphosphorylation of Cbl was paralleled by its co-immunoprecipitation with ErbB-1, which was also impaired in the tion of cell surface ErbB-1 and ErbB-2 has allowed us to discover novel aspects of ligand-induced ErbB receptor absence of ErbB-2 ( Figure 5B ). Unexpectedly, after NDF treatment of T47D/5R cells Cbl was neither tyrosine interplay. First, ErbB receptor interactions induced by various EGF-related growth factors are less diverse than phosphorylated ( Figure 5A ) nor co-immunoprecipitated with ErbB-1 ( Figure 5B ). It is noteworthy that a similar previously suggested (Cohen,B.D. et al., 1996; Riese et al., 1995 Riese et al., , 1996 Zhang et al., 1996) and follow a strict extent of ErbB-1 activation in response to HB-EGF was hierarchy, with ErbB-2 being the preferred heterodimeriz-1987). Thus, ErbB-2 may first dimerize with ErbB-1 in response to EGF and then, in its phosphorylated and ation partner for all other ErbB proteins. Second, ErbB-2 is involved in horizontal signaling, mediating the lateral activated state, be released and dimerize with and phosphorylate ErbB-3 or ErbB-4. Alternatively, the formation transmission of signals between ErbB receptors. Third, ErbB-2 enhances and prolongs the MAPK signaling casof ErbB receptor oligomers may occur (Lax et al., 1991) . Therefore, EGF-induced activation of ErbB-3 and ErbB-4 cade in response not only to EGF and NDF but also in response to BTC. Fourth, the data could be the result of receptor transphosphorylation occuring only within ErbB-1-ErbB-2-ErbB-3 or ErbB-1-presented in this paper demonstrate that a given ErbB receptor can acquire different signaling properties ErbB-2-ErbB-4 trimers. In both models, ErbB-2 is required to activate NDF receptors in response to EGF. depending on its dimerization partner. Finally, our results suggest that ErbB-1 is not the only receptor for HB-EGF.
However, future studies will be required to delineate the precise mechanism of lateral transmission of signals. NDF binds and activates ErbB-3 and ErbB-4, triggers ErbB-2-containing heterodimers and induces ErbB-2 tyro-BTC is a ligand for ErbB-1 and ErbB-4 (Beerli and Hynes, 1996; Riese et al., 1996) and BTC-induced sine phosphorylation . Moreover, the intracellular retention of ErbB-2 results in impaired ErbB-1-ErbB-2 and ErbB-4-ErbB-2 heterodimers have been reported (Riese et al., 1996) . Consistent with this, NDF-induced activation of both receptors (Beerli et al., 1995; . In contrast, we never down-regulation of ErbB-1 results in diminished ErbB-2 phosphorylation and the absence of cell surface ErbB-2 observed an increase in ErbB-1 tyrosine phosphorylation in response to NDF, suggesting that no ErbB-1-containing results in impaired BTC-induced ErbB-1 and ErbB-4 activation, suggesting that BTC also signals through heterodimers are formed. Moreover, in T47D cells depleted of ErbB-1, NDF activated ErbB-2, ErbB-3 and ErbB-4 to ErbB-2-containing heterodimers. Although BTC could presumably induce ErbB-4-ErbB-1 heterodimers, downthe same extent as in the control cells, indicating that ErbB-1 does not participate in NDF signaling. Other regulation of ErbB-1 in T47D cells does not affect ErbB-4 activation, suggesting that ErbB-4-ErbB-2 heterodimers, reports have presented evidence for NDF-induced formation of ErbB-3-ErbB-1 and ErbB-4-ErbB-1 heterodimers and possibly ErbB-4 homodimers, are sufficient for BTC to activate ErbB-4. BTC was also able to elevate tyrosine when these pairs of receptors were co-expressed in host cell lines that do not bear endogenous ErbB proteins phosphorylation of ErbB-3 when co-expressed with ErbB-1 in Ba/F3 cells, but not when co-expressed with (Riese et al., 1995; Cohen,B.D. et al., 1996; PinkasKramarski et al., 1996; Zhang et al., 1996) . In accordance ErbB-4, implying that at least ErbB-1-ErbB-3 heterodimers are possible (Riese et al., 1996) . However, in the with these findings, NDF readily induced ErbB-1 tyrosine phosphorylation and association with the adaptor protein human epithelial cell lines T47D and A431, BTC-induced tyrosine phosphorylation of ErbB-3 was dramatically SHC in T47D cells devoid of cell surface ErbB-2. These results directly show, for the first time, that ligandimpaired in the absence of ErbB-2, indicating that, by analogy with the ErbB-1 ligand EGF, BTC activation of induced ErbB receptor heterodimerization follows a strict hierarchy. If no ErbB-2 is available, ErbB-3 and/or ErbB-4
ErbB-3 involves the interplay of three receptors, ErbB-1-ErbB-2-ErbB-3 and ErbB-4-ErbB-2-ErbB-3. are able to heterodimerize with ErbB-1 in response to NDF. However, if the four ErbB proteins are present on
We show that down-regulation of cell surface ErbB-2 has dramatic consequences on downstream signaling the plasma membrane, the NDF receptors preferentially dimerize with ErbB-2.
events elicited by BTC. In particular, intracellular retention of ErbB-2 results in transient ligand-induced MAPK EGF has been found to activate ErbB-3 in cell lines overexpressing ErbB-1 (Kim et al., 1994; Soltoff et al., activity. We previously made a similar observation with EGF and NDF , which correlated 1994). Moreover, co-expression of ErbB-1 with either ErbB-3 or ErbB-4 in cell types lacking endogeneous ErbB with a decreased ligand affinity due to an accelerated offrate (Karunagaran et al., 1996) . Thus, it is reasonable to proteins allows EGF to regulate tyrosine phosphorylation of these receptors (Riese et al., 1995; Cohen,B.D. et al., suspect that ErbB-2-containing heterodimers are not only the high affinity receptors for EGF and NDF, but for all 1996; Zhang et al., 1996) . These results imply that EGF may induce ErbB-1-ErbB-3 and ErbB-1-ErbB-4 EGF-related growth factors. HB-EGF, although to a lesser extent than NDF and heterodimers. However, our experiments demonstrate that the absence of functional ErbB-2 dramatically impairs BTC, is also able to elevate tyrosine phosphorylation of ErbB-4 (Beerli and Hynes, 1996 ; Figure 1B ). Binding of EGF-triggered ErbB-3 and ErbB-4 tyrosine phosphorylation, as well as association of ErbB-3 with the p85
an EGF agonist to ErbB-1 could theoretically trigger ErbB-1-ErbB-4 dimers and subsequently activate ErbB-4. subunit of PtdIns 3-kinase. Significantly, efficient EGFinduced activation of ErbB-3 is dependent on ErbB-2 not Nevertheless, in T47D cells depleted of ErbB-1, HB-EGF, but not EGF, still activated ErbB-4 to the same extent as only in T47D cells, which have low levels of ErbB-1 (7000 molecules/cell), but also in ErbB-1 overexpressing in the control cells, which implies the existence of an additional receptor for HB-EGF. This result is reminiscent A431 cells (1ϫ10 6 molecules/cell). Thus, formation of ErbB-1-ErbB-3 and ErbB-1-ErbB-4 heterodimers cannot of BTC, making it possible that HB-EGF also binds ErbB-1 and ErbB-4. Alternatively, HB-EGF could bind account for activation of NDF receptors by EGF. Instead, it appears that EGF activates ErbB-3 and ErbB-4 via ErbB-3, thereby triggering ErbB-3-ErbB-4 dimers. Indeed, HB-EGF activates ErbB-3 not only in T47D/puro but also ErbB-2. Indeed, in SKBR3 cells an EGF-induced direct ErbB-2-ErbB-3 interaction was detected. It is known that in T47D/R1R cells (our unpublished data). In both cases, a requirement for ErbB-2 for HB-EGF activation of dimerization of receptors is not a static, but rather a dynamic and reversible process (Yarden and Schlessinger, ErbB-4 becomes evident in T47D/5R cells. Further studies will be required to elucidate the mechanism by which HB-EGF activates ErbB-4. It is likely that the diversity of the biological responses triggered by the EGF-related ligands is due to the ability of each different ErbB family member to couple with distinct and specific intracellular signaling pathways (Di Fiore et al., 1990; Taverna et al., 1991; Riese et al., 1995., Beerli and Pinkas-Kramarski et al., 1996) . For instance, ErbB-3 differs from the other receptors in its ability to directly interact with p85 but not with phospholipase Cγ or GTPase activating protein (Fedi et al., 1994) . On the other hand, ErbB-1 seems to be the only ErbB receptor able to interact with and phosphorylate the Cbl proto-oncogene product (Levkowitz et al., 1996) . Moreover, the signal elicited by a receptor heterodimer is not simply defined by addition of the signaling properties of the individual dimerization partners (Alimandi et al., 1995) . Indeed, our results demonstrate that the ability of a specific ErbB protein to recruit downstream signaling molecules is dependent upon its dimerization partner. In particular, all EGF-related peptides induce ErbB-1 to interact with the adaptor protein SHC. However, only ErbB-1 ligands, which activate the receptor mainly by inducing ErbB-1 homodimers and ErbB-1-ErbB-2 heterodimers, but not NDF, which can only activate ErbB-1 by even in the absence of ErbB-2 (Riese et al., 1996) .
In summary, the results presented in this paper allow us to propose a model of ErbB receptor function (Figure but also of ErbB-1 overexpressing tumor cells (Jannot 7). According to this model, ligand-induced ErbB receptor et al., 1996) . Our results suggest that the remarkable dimerization is governed by a strict hierarchy, with ErbB-2 transforming potency of ErbB-2 is due not only to its being the preferred heterodimerization partner of all other ability to heterodimerize with the other ErbB receptors, ErbB proteins. Thus, NDF receptors readily dimerize with but also to its involvement in lateral signaling. ErbB-2 but not with ErbB-1 if all four receptors are present ( Figure 7A, left) . Interactions between NDF receptors and ErbB-1 are only favored in cells engineered to lack cell
Materials and methods
surface ErbB-2 ( Figure 7A, right) . Similarly, the receptors Materials for EGF and BTC also preferentially interact with ErbB-2.
Recombinant human EGF was from Sigma, recombinant human HBHowever, in contrast to NDF receptors, ligand-activated EGF and BTC from R&D Systems. The recombinant human EGF-β1-EGF and BTC receptors have the capability to transactivate like domain of NDF used in all the experiments was a gift from Amgen (Thousand Oaks, CA). Antibodies used were: EGFR-specific mAbs ErbB proteins distinct from ErbB-2. This could at least in EGFR1 (Amersham) and 528 (Santa Cruz Biotechnology) and EGFRpart be due to direct crosstalk, as evidenced in cells specific antiserum 15E (Gullick et al., 1985) , ErbB-2-specific antiserum lacking cell surface ErbB-2 ( Figure 7B and C, right). 21N (Hynes et al., 1989) , ErbB-3-specific affinity purified rabbit polyHowever, the presence of ErbB-2 dramatically enhances clonal antibody C17 (Santa Cruz Biotechnology), ErbB-4-specific mAb transactivation of NDF receptors by ErbB-1, demonstrating oncogenic potential of ErbB-2. Overexpression of ErbB-2 leading to constitutive activation of its kinase is observed Cell culture in many human tumors and frequently correlates with T47D/puro, T47D/5R and T47D/R1R (Graus-Porta et al., 1995; Jannot more malignant disease (Hynes and Stern, 1994) . Moreet al., 1996) and A431/puro and A431/5R cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL) suppleover, ErbB-2 is important not only for growth of ErbB-2
